Shares of Histogenics Corp. (NASDAQ:HSGX) were up 7.5% during trading on Tuesday after Needham & Company raised their price target on the stock from $8.00 to $11.00. Needham & Company currently has a buy rating on the stock. Histogenics Corp. traded as high as $3.32 and last traded at $3.30, with a volume of 59,492 shares traded. The stock had previously closed at $3.07.

Several other analysts have also recently commented on the stock. BTIG Research raised shares of Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 target price for the company in a research note on Thursday, August 11th. Zacks Investment Research raised shares of Histogenics Corp. from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research note on Friday, August 26th. Finally, William Blair cut shares of Histogenics Corp. from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 7th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Histogenics Corp. currently has a consensus rating of “Buy” and an average target price of $7.65.

An institutional investor recently raised its position in Histogenics Corp. stock. First Republic Investment Management Inc. increased its position in shares of Histogenics Corp. (NASDAQ:HSGX) by 315.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 48,455 shares of the company’s stock after buying an additional 36,784 shares during the period. First Republic Investment Management Inc. owned 0.37% of Histogenics Corp. worth $111,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 38.63% of the company’s stock.

The firm’s 50-day moving average price is $2.91 and its 200 day moving average price is $2.29. The company’s market cap is $43.66 million.

Histogenics Corp. (NASDAQ:HSGX) last released its earnings results on Thursday, August 11th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.01. During the same quarter last year, the business earned ($0.58) EPS. Equities research analysts expect that Histogenics Corp. will post ($2.11) earnings per share for the current year.

About Histogenics Corp.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

5 Day Chart for NASDAQ:HSGX

Receive News & Ratings for Histogenics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.